Ultragenyx Pharmaceutical Inc. (RARE)

Name: Ultragenyx Pharmaceutical Inc. (RARE) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001515673 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Ultragenyx Pharmaceutical Inc. reported revenue of $673.00M. Revenue grew 20.2% from the prior annual period.

Key ratios (year ended 2025-12-31)

-79.5%

Operating margin

-85.4%

Net margin

20.2%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-19

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Period ended	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$673.00M	$560.00M	$434.00M	$363.33M	$351.41M	$271.03M	$103.71M	$51.49M	$2.61M	$133.0K
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$1.15M	$1.0K	n/a
R&D Expense	$750.00M	$698.00M	$648.00M	$705.79M	$497.15M	$412.08M	$357.36M	$294.00M	$231.64M	$183.20M
Operating Income	-$535.00M	-$536.00M	-$569.00M	-$648.92M	-$381.74M	-$330.12M	-$424.17M	-$371.37M	-$328.94M	-$248.01M
Depreciation & Amortization	$35.00M	$36.00M	$26.00M	$18.22M	$13.24M	$12.26M	$8.54M	$19.54M	$5.83M	$3.42M
EBITDA	-$500.00M	-$500.00M	-$543.00M	-$630.70M	-$368.50M	-$317.86M	-$415.63M	-$351.83M	-$323.12M	-$244.58M
Net Income	-$575.00M	-$569.00M	-$607.00M	-$707.42M	-$454.02M	-$186.57M	-$402.73M	-$197.61M	-$302.14M	-$245.87M
EPS (Diluted)	-$5.83	-$6.29	-$8.25	-$10.12	-$6.70	-$3.07	n/a	n/a	n/a	n/a
Total Assets	$1.53B	$1.50B	$1.49B	$1.55B	$1.52B	$1.76B	$1.14B	$719.56M	$490.75M	$540.63M
Total Liabilities	$1.60B	$1.24B	$1.22B	$1.19B	$599.84M	$605.18M	$481.73M	$110.65M	$107.30M	$66.65M
Shareholders' Equity	-$80.00M	$255.00M	$275.00M	$352.49M	$922.56M	$1.15B	$653.76M	$608.91M	$383.45M	$473.97M
Cash & Equivalents	$421.00M	$174.00M	$214.00M	$132.94M	$307.58M	$713.53M	$433.58M	$113.43M	$100.49M	$161.12M
Operating Cash Flow	-$466.00M	-$414.00M	-$475.00M	-$380.46M	-$338.69M	-$132.22M	-$345.38M	-$290.57M	-$253.84M	-$160.97M
Capital Expenditures	$6.00M	$7.00M	$44.00M	$116.12M	$73.09M	$43.91M	$24.83M	$4.08M	$2.79M	$10.19M
Free Cash Flow	-$472.00M	-$421.00M	-$519.00M	-$496.59M	-$411.79M	-$176.12M	-$370.21M	-$294.64M	-$256.64M	-$171.16M
Shares Outstanding	96.60M	92.50M	82.32M	70.20M	69.34M	66.82M	57.84M	50.86M	44.17M	41.24M
Weighted Average Diluted Shares	98.60M	90.50M	73.50M	69.91M	67.80M	60.85M	n/a	n/a	n/a	n/a
EPS (Basic)	-$5.83	-$6.29	-$8.25	-$10.12	-$6.70	-$3.07	n/a	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView